A comparative economic analysis of simvastatin versus atorvastatin: Results of the surrogate marker cost-efficacy (SMaC) study

Clinical Therapeutics

Volumn 21, Issue 10, 1999, Pages 1788-1796

  Badia, Xavier ^a,c   Russo, Pierluigi ^b   Attanasio, Ermanno ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Inst Universitari Salut Pub C   (Spain)

Author keywords

Atorvastatin; Cholesterol; Cost; Outcomes; Simvastatin

Indexed keywords

ATORVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0032693869     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80056-3     Document Type: Article

References (19)

1. 1. Goa KL, Barradell LB, McTavish D. Simvastatin: A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease. Pharmacoecomomics. 1997; 11:89-110.
2. 2. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-1389.
3. 3. Pedersen TR, Kjekshus J, Ber K, et al. Cholesterol lowering and the use of health care resources: Results of the Scandinavian Simvastatin Survival Study. Circulation. 1996;93:1796-1802.
4. 4. Jönsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering: Results of the Scandinavian Simvastatin Survival Study (4S). Eur Heart J. 1996;17:1001-1007.
5. 5. Johannesson M, Jönsson B, Kjekshus J, et al, for the Scandinavian Simvastatin Survival Study Group. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 1997;336:332-336.
6. 6. Dujovne CA. New lipid lowering drugs and new effects of old drugs. Curr Opin Lipidol. 1997;8:362-368.
7. 7. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol. 1997; 80:39-44.
8. 8. Best J, Dart A, Hamilton Craig I, et al. A one-year study comparing atorvastatin and simvastatin in patients with hypercholesterolemia. In: Program and abstracts of the 66th Congress of the European Atherosclerosis Society; July 1996; Florence, Italy. Abstract.
9. 9. Parke-Davis-Warner Lambert Company. Studies Comparing Atorvastatin to Other Lipid Lowering Agents. In: US FDA Regulatory Filing for Atorvastatin. Section 7.2:48-55.
10. 10. Data on file. Whitehouse Station, NJ: Merck & Co., Inc.; 1999.
11. 11. European Central Bank. Determination of euro conversion rates [press release]. December 31, 1998. Available at: http://www. ecb.int/press/pr981231_2.htm. Accessed August 10, 1999.
12. 12. US Census Bureau. IDB Data Access. 1998 Figures. Available at: http://www. census.gov/ipc/www/idbprint.html. Accessed August 10, 1999.
13. 13. Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: A reappraisal. Drug Saf. 1996;14:11-24.
14. 14. Drummond MF, Heyse J, Cook J, McGuire A. Selection of end-points in economic evaluations of coronary heart disease interventions. Med Decis Making. 1993;13:184-190.
15. 15. Jones P, Kafonek S, Laurora I, et al. Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients with Hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582-587.
16. 16. Crouse J, Frohlich J, Ose L, et al. Simvastatin and atorvastatin have different effects on HDL cholesterol and apolipoprotein A-1. Presented at the American College of Cardiology Scientific Sessions; March 8, 1999; New Orleans, Louisiana. Abstract 1075-73.
17. 17. Castelli W. Lipoproteins and cardiovascular disease: Biological basis and epidemiological studies. Value Health. 1998;1: 105-109.
18. 18. Waters D, Pitt B, Brown V, et al. Aggressive Lipid Lowering Versus Coronary Angioplasty in Patients with Inducible Myocardial Ischemia: An AVERT substudy. Presented at the American College of Cardiology Scientific Sessions; March 8, 1999; New Orleans, Louisiana. Abstract 1066-137.
19. 19. Report from the Committee of Principal Investigators. WHO Cooperative Trial on Primary Prevention of Ischaemic Heart Disease with Clofibrate to Lower Serum Cholesterol: Final mortality follow-up. Lancet. 1984;2:600-604.